In conclusion, these results suggest that whilst JADE2 mRNA and protein are not significantly altered in NSCLC, their expression has prognostic value, and may have potential clinical use for predicting or stratifying patients who will have better 5-year overall survival. This evidence concerns the gene JADE2 and non-small cell lung carcinoma.